Clinical Trial for the Safety and Efficacy of Murine CD79b CAR-T Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 02 Nov 2021
At a glance
- Drugs CD79b CAR-T Cell Therapy-Yake Biotechnology (Primary)
- Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 06 Nov 2020 New trial record